Frequently asked
questions

The cost of participating in our clinical trials depends on the clinical trial and method of administration. One systemic intravenous dose costs 25 000 USD. Inclusion in our Clinical trials starts at $16,500. 

Advanced cell therapy production is costly due to strict regulations that ensure quality and safety for patients. A specialised production facility, highly skilled personnel, and expensive equipment and consumables are required. 

MSCs function through cell to cell contact and the release of bioactive molecules, such as growth factors, cytokines, and exosomes, stimulating the body’s natural healing processes.

When injected into the body, MSCs interact with the immune system by being engulfed by immune cells such as macrophages. This triggers effects that suppress inflammation and promote tissue regeneration.

Cellcolabs Clinical utilise cells from Cellcolabs AB. These high-quality cells are sourced from bone marrow donated by healthy individuals aged 18-30.

Donors undergo rigorous health checks, and the cells are cultured in Cellcolabs’ advanced facility in Stockholm, following MPA regulations and ethical standards. 

Mesenchymal Stem Cells (MSCs) sourced from bone marrow have been extensively researched in scientific studies over several decades. 

A meta-analysis published in 2021 reviewed 62 randomised clinical trials and concluded that MSC treatment was safe compared to placebo. No serious adverse events were reported across the included studies. ² 

Our clinical trials are focused on exploring the use of MSCs in prevention of cardiovascular disease, ageing frailty and musculoskeletal injuries and degeneration. All our clinical studies have clear inclusion and exclusion criteria.   

Generally, one should not participate in a research study if it comes at the expense of other ongoing or planned treatments. All our clinical studies have clear inclusion and exclusion criteria. 

Cellcolabs Clinical provides both systemic and local injections of MSC within clinical trials. Systemic treatments involve a dose of 100 million cells. Local injections, such as for knee osteoarthritis, involve 50 million cells. 

Depending on the clinical trial, systemic doses of MSC may be delivered as a slow intravenous infusion over 30 minutes, or as a local injection under ultrasound guidance directly into a joint or ligament. 

Based on extensive safety studies, MSCs have not shown association with any severe or long–term side effects. Most individuals feel well after the treatment. However, there is a small risk of experiencing tenderness around the injection site and a mild fever or tiredness in the days following the treatment. 

Before treatment administration, you will be examined by the study doctor and may undergo specific tests, depending on the trial. The treatment procedure takes between 30 and 60 minutes. After MSC administration, you will spend an additional 90 minutes at the clinic for observation. 

MSCs have anti-inflammatory, regenerative, and immunomodulatory properties, and research has indicated their potential for treating, alleviating, or even preventing various medical conditions. However, the effects of MSC treatment may vary between individuals and participation in a clinical trial does not guarantee any results. The purpose of a clinical trial is for researchers to learn more about the possible effects of an intervention or treatment. 

There have been no reported cases of tumour formation resulting from MSC treatment in clinical trials. 

Yes, all clinical trials are approved by local authorities and national ethics committees.